IZERVAY Gets FDA Patent Extension Green Light: Business as Usual
Published Date: 1/5/2026
Notice
Summary
The FDA has officially set the review period for IZERVAY, a human drug, so its patent can be extended. This affects the drug’s makers, who now have clear deadlines to challenge or confirm these dates by early 2026. If all goes well, the patent extension could give them more time to protect their invention and potentially earn more money.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in